General Malaise
Footballguy
Lol. I was on a call and was editing. Core, non COVID genetics testing (they’ve also made acquisitions on cancer testing) is predicted at $120M which seems like an easily beatable number. Here’s the transcript of their earnings call:
https://www.fool.com/earnings/call-transcripts/2022/02/23/fulgent-genetics-inc-flgt-q4-2021-earnings-call-tr/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
One thing that they seem excited about is spatial genomics which they see as their next gen (past their current next gen) and this is an article about their investment:
https://finance.yahoo.com/news/fulgent-genetics-announces-strategic-investment-210500553.html
There are two things that really excite me about this company. First, they were able to pivot and make an absolute killing on COVID testing the past couple years. That tells me that they’ll take full advantage of opportunities and be able to deliver. Second, they now have a cash hoard to make investments both to increase their core revenue and expand their markets but also be able to invest in new technology to make sure they are always ahead of the game.
Thank you, GB.